BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is a particularly vascularized solid
tumor where the Raf/MEK/ERK pathway is activated; suggesting that inhibition of this …

Sorafenib targets the Raf/mitogen-activated protein kinase, VEGF, and platelet-derived
growth factor pathways and prolongs survival patients in advanced hepatocellular …

Purpose: Sorafenib has proved survival benefit for patients with advanced hepatocellular
carcinoma (HCC). This study explored whether the efficacy of sorafenib can be improved by …

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Vascular
endothelial growth factor, platelet derived growth factor and the Raf/mitogen‐activated …

Hepatocellular carcinoma (HCC) is the fifth most common primary cancer and second
largest cause of cancer‐related death worldwide. The first‐line oral chemotherapeutic agent …

Angiogenesis and signaling through the RAF/mitogen-activated protein/extracellular signal-
regulated kinase (ERK) kinase (MEK)/ERK cascade have been reported to play important …

BACKGROUND & AIMS: The combination of erlotinib with sorafenib is currently being
investigated in a phase III RCT. We studied the effect of erlotinib and sorafenib on HCC in a …

Sorafenib displays a limited efficacy for advanced hepatocellular carcinoma (HCC). Some
patients with HCC initially respond to sorafenib, but eventually succumb to the disease …

Background: Sorafenib, an oral multi-kinase inhibitor of rapidly accelerated fibrosarcoma;
vascular endothelial growth factor receptor-2/3, platelet-derived growth factor receptor, c-Kit …

Background: Sorafenib is an oral multi-kinase inhibitor that inhibits hepatocellular carcinoma
(HCC) via the Ras/Raf/MAPK pathway. However, sorafenib loses effectiveness because …